| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.OPHTHA.2013.09.015 |
| P698 | PubMed publication ID | 24289915 |
| P2093 | author name string | Charles P Semba | |
| Eugene B McLaurin | |||
| Gail L Torkildsen | |||
| Francis A D'Ambrosio | |||
| John D Sheppard | |||
| John D Lonsdale | |||
| Kathryn S Kennedy | |||
| OPUS-1 Study Group | |||
| Richard A Eiferman | |||
| P433 | issue | 2 | |
| P921 | main subject | eye disease | Q3041498 |
| lifitegrast | Q23044263 | ||
| P304 | page(s) | 475-483 | |
| P577 | publication date | 2013-11-26 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | |
| P478 | volume | 121 |
| Q43200676 | A novel multi-parameter assay to dissect the pharmacological effects of different modes of integrin αLβ2 inhibition in whole blood. |
| Q100558870 | A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation |
| Q89906657 | Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial |
| Q48095233 | Current Anti-Integrin Therapy for Ocular Disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q26746232 | Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease |
| Q39404635 | Dry Eye Management: Targeting the Ocular Surface Microenvironment. |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q36252489 | Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment |
| Q91885064 | Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies |
| Q51836466 | Effects of Aging in Dry Eye. |
| Q35732401 | Effects of Dry Eye Therapies on Environmentally Induced Ocular Surface Disease |
| Q38198760 | Emerging drugs for allergic conjunctivitis |
| Q33585580 | Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve |
| Q49834557 | Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. |
| Q36050556 | Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model. |
| Q39025675 | LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease |
| Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
| Q59794055 | Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report |
| Q45037685 | Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials |
| Q38608475 | Lifitegrast for the treatment of dry eye disease in adults |
| Q33739879 | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy |
| Q26774853 | Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease |
| Q37591609 | Lifitegrast: A novel drug for treatment of dry eye disease |
| Q93137705 | Lifitegrast: a novel drug for patients with dry eye disease |
| Q64106425 | Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity |
| Q47442388 | Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. |
| Q26775356 | Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics |
| Q33752165 | Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases |
| Q47268214 | Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs |
| Q49261503 | Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. |
| Q38234039 | Phase II drugs under investigation for allergic conjunctivitis |
| Q41615871 | Pro-Secretory Activity and Pharmacology in Rabbits of an Aminophenyl-1,3,5-Triazine CFTR Activator for Dry Eye Disorders |
| Q36877000 | Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study |
| Q27342865 | SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model |
| Q36812082 | Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease |
| Q89349313 | Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast |
| Q38569837 | The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline |
| Q90351231 | The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options |
| Q41405231 | The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye. |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
| Q47424328 | Update in Current Diagnostics and Therapeutics of Dry Eye Disease. |
| Q47100458 | Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review |
| Q50039889 | [Novel current and future therapy options for treatment of dry eye disease]. |
Search more.